Abstract
Aspirin-exacerbated respiratory disease (AERD) is a triad of asthma, nasal polyposis, and intolerance to nonsteroidal anti-inflammatory drugs. Although AERD affects 7% of patients with asthma and 10% of patients with nasal polyposis, it may affect up to 25% to 30% of patients with both asthma and nasal polyps. 1 White AA Stevenson DD. Aspirin-exacerbated respiratory disease. N Engl J Med. 2018; 379: 2281-2282 PubMed Google Scholar Furthermore, although many patients are diagnosed based on their clinical history, the gold standard of diagnosis remains an aspirin challenge. After the diagnosis of AERD, treatment is often stepwise, aimed at controlling both lower and upper airway inflammation with topical corticosteroids and leukotriene modifiers. For patients failing typical therapies, aspirin desensitization has been found to improve symptoms, decrease reliance on medications, including systemic steroids, and increase the interval between the surgical interventions for nasal polyposis. 2 Berges-Gimeno MP Simon RA Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2003; 111: 180-186 Abstract Full Text Full Text PDF PubMed Scopus (265) Google Scholar
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
